Literature DB >> 9770720

Longitudinal study of body cell mass depletion and the inflammatory response in cancer patients.

D C McMillan1, H R Scott, W S Watson, T Preston, R Milroy, C S McArdle.   

Abstract

There is recent evidence that the inflammatory response may be important in the disproportionate loss of body cell mass in cancer patients. To examine this further, 18 male patients with lung or gastrointestinal cancer were studied over a 12-week period. In addition to weight, anthropometry, C-reactive protein (marker of the inflammatory response), albumin, and total body potassium were measured at baseline and 12 weeks. When those patients who lost total body potassium were compared with those who had not, there was a significant increase in the baseline and 12-week C-reactive protein concentrations (p < 0.05). The reduction in total body potassium was also associated with a reduction in triceps skinfold thickness (p < 0.05). There were significant correlations between the mean C-reactive protein concentration and the relative (r = -0.846, p < 0.001) and absolute (r = -0.806, p < 0.001) change in total body potassium over the follow-up period. This study demonstrates the association of a chronic inflammatory response with the rate of loss of body cell mass observed in cancer patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9770720     DOI: 10.1080/01635589809514687

Source DB:  PubMed          Journal:  Nutr Cancer        ISSN: 0163-5581            Impact factor:   2.900


  33 in total

1.  The relationship between an inflammation-based prognostic score (Glasgow Prognostic Score) and changes in serum biochemical variables in patients with advanced lung and gastrointestinal cancer.

Authors:  D J F Brown; R Milroy; T Preston; D C McMillan
Journal:  J Clin Pathol       Date:  2006-04-27       Impact factor: 3.411

2.  Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer.

Authors:  Donald C McMillan; Joseph E M Crozier; Khalid Canna; Wilson J Angerson; Colin S McArdle
Journal:  Int J Colorectal Dis       Date:  2007-01-24       Impact factor: 2.571

3.  Prognostic value of the Glasgow Prognostic Score in metastatic colorectal cancer in the era of anti-EGFR therapies.

Authors:  Johann Dréanic; Marianne Maillet; Marion Dhooge; Olivier Mir; Catherine Brezault; François Goldwasser; Stanislas Chaussade; Romain Coriat
Journal:  Med Oncol       Date:  2013-07-10       Impact factor: 3.064

4.  Inflammation-based prognostic scores as indicators to select candidates for primary site resection followed by multimodal therapy among colorectal cancer patients with multiple metastases.

Authors:  Tadanobu Shimura; Yuji Toiyama; Susumu Saigusa; Hiroki Imaoka; Masato Okigami; Hiroyuki Fujikawa; Junichiro Hiro; Minako Kobayashi; Masaki Ohi; Toshimitsu Araki; Yasuhiro Inoue; Keiichi Uchida; Yasuhiko Mohri; Masato Kusunoki
Journal:  Int J Clin Oncol       Date:  2017-03-15       Impact factor: 3.402

5.  Comparison of the Glasgow Prognostic Score (GPS) and the modified Glasgow Prognostic Score (mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer.

Authors:  Heng Fan; Zhen-Yi Shao; Yuan-Yuan Xiao; Zhi-Hui Xie; Wen Chen; Hua Xie; Guo-You Qin; Nai-Qing Zhao
Journal:  J Cancer Res Clin Oncol       Date:  2016-02-11       Impact factor: 4.553

6.  Modified glasgow prognostic score in patients with small-cell lung cancer.

Authors:  Koichi Kurishima; Hiroko Watanabe; Hiroichi Ishikawa; Hiroaki Satoh; Nobuyuki Hizawa
Journal:  Mol Clin Oncol       Date:  2017-05-12

Review 7.  The role of C-reactive protein as a prognostic indicator in advanced cancer.

Authors:  Fade Aziz Mahmoud; Nilo I Rivera
Journal:  Curr Oncol Rep       Date:  2002-05       Impact factor: 5.075

Review 8.  Hypoalbuminemia in colorectal cancer prognosis: Nutritional marker or inflammatory surrogate?

Authors:  Bassel Nazha; Elias Moussaly; Mazen Zaarour; Chanudi Weerasinghe; Basem Azab
Journal:  World J Gastrointest Surg       Date:  2015-12-27

9.  Amino acid metabolism and inflammatory burden in ovarian cancer patients undergoing intense oncological therapy.

Authors:  E L Dillon; Elena Volpi; Robert R Wolfe; Sandeep Sinha; Arthur P Sanford; Concepcion D Arrastia; Randall J Urban; Shanon L Casperson; Douglas Paddon-Jones; Melinda Sheffield-Moore
Journal:  Clin Nutr       Date:  2007-09-04       Impact factor: 7.324

10.  The role of systemic inflammatory and nutritional blood-borne markers in predicting response to neoadjuvant chemotherapy and survival in oesophagogastric cancer.

Authors:  Fergus Noble; James Hopkins; Nathan Curtis; Jamie J Kelly; Ian S Bailey; James P Byrne; Adrian C Bateman; Andrew R Bateman; Timothy J Underwood
Journal:  Med Oncol       Date:  2013-05-21       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.